WO2000042995A2 - Derives anticonvulsivants utiles dans le traitement de la migraine dite transformee - Google Patents

Derives anticonvulsivants utiles dans le traitement de la migraine dite transformee Download PDF

Info

Publication number
WO2000042995A2
WO2000042995A2 PCT/US2000/001382 US0001382W WO0042995A2 WO 2000042995 A2 WO2000042995 A2 WO 2000042995A2 US 0001382 W US0001382 W US 0001382W WO 0042995 A2 WO0042995 A2 WO 0042995A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
alkyl
hydrogen
compound
headache
Prior art date
Application number
PCT/US2000/001382
Other languages
English (en)
Other versions
WO2000042995A3 (fr
Inventor
Doreen L. Potter
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Priority to AU35826/00A priority Critical patent/AU3582600A/en
Publication of WO2000042995A2 publication Critical patent/WO2000042995A2/fr
Publication of WO2000042995A3 publication Critical patent/WO2000042995A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • Transformed migraine is a condition in which migraine sufferers, because of increased analgesic or ergotamine usage, progress to a syndrome of daily headache compounded by habituation and increasing dependence on analgesic medication. It has a separate classification under the guidelines of the International Headache Society ("IHS"). This separate classification has been supported by the Second International Workshop on Headache (Headache Classification Committee of the International Headache Society, Cranial Neuralgias and Facial Pain, Cephalgia 8 (Supp. 7):l-96, 1988). Transformed migraine is distinctly different from chronic tension type headache ("CTTH”) in its classification by the IHS. (Headache Classification Committee of the International Headache Society, (Oleson) 1988).
  • CTTH chronic tension type headache
  • the classic transformed migraine patient is female (F:M ratio is 3:1) and approximately 35-40 years old with a history of migraine from the teens.
  • the onset of transformation is gradual in 80%, sudden in 20%.
  • the episodes are aggravated by menstruation and ovulation, and analgesic abuse is present in at least 40% of subjects.
  • the headache wakes the patient from sleep and, as a consequence, 71% have difficulty in initiation and maintenance of sleep.
  • treatment is withdrawal of all medication (Mathew et al, Transformed or Evolutive Migraine Headache, Headache 27:102-106, 1987; Mathew, Rebound Headache, American Association for the Study of Headache, Scottsdale Nov. 1998).
  • Rj, R 2 , R 3 , R 4 and R 5 are as defined hereinafter are useful in treating transformed migraine.
  • X is CH2 or oxygen; Rl is hydrogen or - alkyl; and
  • R2, R3, R4 and R5 are independently hydrogen or CrC 3 alkyl and, when X is CH2, R4 and R5 may be alkene groups joined to form a benzene ring and, when X is oxygen, R2 and R3 and/or R4 and R5 together may be a methylenedioxy group of the following formula (II):
  • R6 and R7 are the same or different and are hydrogen, Cj-C 3 alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
  • Rl in particular is hydrogen or alkyl of about 1 to 4 carbons, such as methyl, ethyl, iso- propyl, n-propyl, n-butyl, isobutyl, sec-butyl and t-butyl.
  • Alkyl throughout this specification includes straight and branched chain alkyl.
  • Alkyl groups for R2, R3, R4, R5, R and R7 are of about 1 to 3 carbons and include methyl, ethyl, iso-propyl and n- propyl.
  • a particular group of compounds of formula (I) is that wherein X is oxygen and both R2 and R3 and R4 and R5 together are methylenedioxy groups of the formula (II), wherein R6 and R7 are both hydrogen both alkyl or combine to form a spiro cyclopentyl or cyclohexyl ring, in particular where R6 and R7 are both alkyl such as methyl.
  • a second group of compounds is that wherein X is CH2 and R4 and R5 are joined to form a benzene ring.
  • a third group of compounds of formula (I) is that wherein both R2 and R3 are hydrogen.
  • a particularly preferred compound for use in the methods of the present invention is 2,3:4,5-bis-O-(l-methylethylidene)- ⁇ -D-fructopyranose sulfamate, known as topiramate.
  • Topiramate has the following structural formula
  • the compounds of formula (I) may be synthesized by the following methods:
  • the chlorosulfate of the formula RCH2OSO2CI may then be reacted with an amine of the formula R1NH2 at a temperature of abut 40° to 25° C in a solvent such as methylene chloride or acetonitrile to produce a compound of formula (I).
  • a solvent such as methylene chloride or acetonitrile.
  • the starting materials of the formula RCH2OH may be obtained commercially or as known in the art.
  • starting materials of the formula RCH2OH wherein both R2 and R3 and R4 and R5 are identical and are of the formula (II) may be. obtained by the method of R. F. Brady in Carbohydrate Research, Vol. 14, p. 35 to 40 (1970) or by reaction of the trimethylsilyl enol ether of a R6COR7 ketone or aldehyde with fructose at a temperature of about 25° C, in a solvent such a halocarbon, e.g. methylene chloride in the presence of a protic acid such as hydrochloric acid or a Lewis Acid such as zinc chloride.
  • the trimethylsilyl enol ether reaction is described by G. L. Larson et al in J. Org. Chem. Volaa 38, No. 22, p. 3935 (1973).
  • carboxylic acids and aldehydes of the formulae RCOOH and RCHO may be reduced to compounds of the formula RCH2OH by standard reduction techniques, e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a temperature of about 0° to 100° C, e.g. as described by H.O. House in "Modern Synthetic Reactions", 2nd Ed., pages 45 to 144 (1972).
  • standard reduction techniques e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a temperature of about 0° to 100° C, e.g. as described by H.O. House in "Modern Synthetic Reactions", 2nd Ed., pages 45 to 144 (1972).
  • the compounds of formula I may also be made by the processes disclosed in U.S. Patent Nos. 4,513,006, 5,387,700 and 5,387,700, all of which are incorporated herein by reference. More particularly, topiramate may be prepared following the process described in Examples 1 to 3 of U.S. 5,387,700.
  • the compounds of formula I include the various individual isomers as well as the racemates thereof, e.g., the various alpha and beta attachments, i.e., below and above the plane of the drawing, of R2, R3, R4 and R5 on the 6-membered ring.
  • the oxygen of the methylenedioxy group (II) are attached on the same side of the 6- membered ring.
  • transformed migraine refers to and includes the conditions known as transformed headache, rebound headache, analgesic rebound headache, ergotamine rebound headache, chronic daily headache, and drug induced headache.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • a compound of formula (I) may be employed at a daily dosage in the range of about 15 mg to about 1000 mg, preferably, about 50 mg to about 400 mg, most preferably, about 100 mg to about 300 mg for an average adult human, administered one to four times per day, preferably, one to two times per day.
  • a unit dose typically contains about 25 to about 200 mg of the active ingredient.
  • topiramate is administered as follows: one 25 mg tablet h.s. for one week then, two 25 mg tablets h.s. for one week then, three 25 mg tablets b.i.d. for one week then, four 25 mg tablets b.i.d.
  • Patient keeps a migraine calendar and is reevaluated in 4 weeks. If improved, patient is switched to 100 mg tablets bid. If only partial improvement is seen, dose is increased as follows:
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
  • one or more sulfamate compounds of formula (I) are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, by suppository, or parenteral.
  • a pharmaceutical carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, by suppository, or parenteral.
  • any of the usual pharmaceutical media may be employed.
  • suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
  • suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. Suppositories may be prepared, in which case cocoa butter could be used as the carrier.
  • the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable solutions may also be prepared in which case appropriate stabilizing agents may be employed.
  • Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent.
  • the tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.
  • compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder injection, teaspoonful, suppository and the like from about 25 to about 200 mg of the active ingredient.
  • dosage unit e.g., tablet, capsule, powder injection, teaspoonful, suppository and the like from about 25 to about 200 mg of the active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés anticonvulsivants, utiles dans le traitement de la migraine dite transformée.
PCT/US2000/001382 1999-01-21 2000-01-20 Derives anticonvulsivants utiles dans le traitement de la migraine dite transformee WO2000042995A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35826/00A AU3582600A (en) 1999-01-21 2000-01-20 Anticonvulsant derivatives useful in treating transformed migraine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11654499P 1999-01-21 1999-01-21
US60/116,544 1999-01-21

Publications (2)

Publication Number Publication Date
WO2000042995A2 true WO2000042995A2 (fr) 2000-07-27
WO2000042995A3 WO2000042995A3 (fr) 2000-11-30

Family

ID=22367829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001382 WO2000042995A2 (fr) 1999-01-21 2000-01-20 Derives anticonvulsivants utiles dans le traitement de la migraine dite transformee

Country Status (3)

Country Link
AR (1) AR022321A1 (fr)
AU (1) AU3582600A (fr)
WO (1) WO2000042995A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084490B2 (en) 2004-06-16 2011-12-27 Janssen Pharmaceutica N.V. Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8283478B2 (en) 2005-05-20 2012-10-09 Janssen Pharmaceutica Nv Process for preparation of sulfamide derivatives
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN110346004A (zh) * 2019-08-16 2019-10-18 杭州山科智能科技股份有限公司 一种双声道超声时差法的流量测量数据融合方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
WO1997013510A1 (fr) * 1995-10-13 1997-04-17 New England Medical Center Hospitals, Inc. Traitement de la migraine
WO1998015270A1 (fr) * 1996-10-08 1998-04-16 Ortho Pharmaceutical Corporation Derives d'anticonvulsifs utiles dans le traitement de la douleur neuropathique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
WO1997013510A1 (fr) * 1995-10-13 1997-04-17 New England Medical Center Hospitals, Inc. Traitement de la migraine
WO1998015270A1 (fr) * 1996-10-08 1998-04-16 Ortho Pharmaceutical Corporation Derives d'anticonvulsifs utiles dans le traitement de la douleur neuropathique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KUZNIECKY R ET AL: "Topiramate increases cerebral GABA in healthy humans." NEUROLOGY, (1998 AUG) 51 (2) 627-9. , XP000923467 *
ROTHROCK, J. F. (1) ET AL: "A differential response to treatment with divalproex sodium in patients with intractable headache." CEPHALALGIA, (1994) VOL. 14, NO. 3, PP. 241-244. , XP000924812 *
SHUAIB A (REPRINT) ET AL: "Topiramate in migraine prophylaxis: a pilot study." CEPHALALGIA, (MAY 1999) VOL. 19, NO. 4, PP. 379-380. PUBLISHER: SCANDINAVIAN UNIVERSITY PRESS, PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY. ISSN: 0333-1024., XP000923377 UNIV ALBERTA, EDMONTON, AB T6G 2M7, CANADA *
STOREY, JAMES R. (1) ET AL: "Potential role of topiramate (TPM) in the treatment of intractable daily headache: A retrospective pilot study." NEUROLOGY, (APRIL 12, 1999) VOL. 52, NO. 6 SUPPL. 2, PP. A211. MEETING INFO.: 51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY TORONTO, ONTARIO, CANADA APRIL 17-24, 1999 AMERICAN ACADEMY OF NEUROLOGY. , XP000921300 *
TRAN, BIHN N. (1) ET AL: "Can valproate prevent migraine headaches." JOURNAL OF PHARMACY TECHNOLOGY, (1997) VOL. 13, NO. 4, PP. 163-168. , XP000925386 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084490B2 (en) 2004-06-16 2011-12-27 Janssen Pharmaceutica N.V. Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8283478B2 (en) 2005-05-20 2012-10-09 Janssen Pharmaceutica Nv Process for preparation of sulfamide derivatives
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10363224B2 (en) 2013-03-13 2019-07-30 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10172878B2 (en) 2013-03-15 2019-01-08 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
CN110346004A (zh) * 2019-08-16 2019-10-18 杭州山科智能科技股份有限公司 一种双声道超声时差法的流量测量数据融合方法
CN110346004B (zh) * 2019-08-16 2020-08-21 杭州山科智能科技股份有限公司 一种双声道超声时差法的流量测量数据融合方法

Also Published As

Publication number Publication date
AR022321A1 (es) 2002-09-04
AU3582600A (en) 2000-08-07
WO2000042995A3 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
US6319903B1 (en) Anticonvulsant derivatives useful in treating cluster headaches
AU774282B2 (en) Anticonvulsant derivatives useful in reducing blood glucose levels
AU775849B2 (en) Anticonvulsant derivatives useful in lowering blood pressure
AU774732B2 (en) Anticonvulsant derivatives useful in lowering lipids
WO2000042995A2 (fr) Derives anticonvulsivants utiles dans le traitement de la migraine dite transformee
WO2000061140A1 (fr) Derives anticonvulsivants utiles pour entretenir une perte de poids
CA2267945C (fr) Derives d'anticonvulsifs utiles dans le traitement de la douleur neuropathique
AU763601B2 (en) Anticonvulsant derivatives useful in treating autism
AU764703B2 (en) Use of anticonvulsant derivatives for treating bulimia nervosa
CA2362336C (fr) Derives d'anticonvulsivant utilises dans le traitement des tremblements essentiels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase